Table 3 .
Clinical and immunological status at the time of biological and histological recurrence in all patients who had recurrence of autoimmune hepatitis
| Patient (OLT) | Pre-OLT autoantibody titre | HLA DR status (donor/ recipient) |
Duration of follow up at the time of histological recurrence (y) | Cause of biopsy | AST/ALT (IU/l) (N<35/N<43) | HCV antibody/ HCV RNA | Autoantibody titre | Treatment |
|---|---|---|---|---|---|---|---|---|
| Group 1 | ||||||||
| 51 | SMA=1:640 | 3,5/13,15 | 1 | Protocol | 20/25 | (−)/(−) | SMA=1:640 | 10 mg P, 1.2 ml×3 C, 50 mg A |
| 155 | SMA=1:640 | 5,7/1,4 | 2 | Protocol | 34/42 | (−)/(−) | SMA=1:640, anti-SLA+ | 10 mg P, (0.5 ml×2) C, 50 mg A |
| 205 | NA | 5,5/3,16 | 5 | Protocol | 48/40 | (−)/(−) | ANA=1:80, SMA=1:160, anti-SLA− | 10 mg P, 200 mg C, 50 mg A |
| 421 | SMA=1:1280 | 7,13/3,3 | 2 | Protocol | 54/90 | (+)/(+) | ANA=1:80, anti-SMA=1:80, anti-SLA− | 10 mg P, 0.5 ml×2 C, 50 mg A |
| Group 2 | ||||||||
| 86 | Anti-LKM=1:640 | 5,5/7,10 | 0.6 | Abnormal liver function tests | 160/405 | (+)/(+) | Anti-LKM−, ANA−, SMA− | 17.5 mg P, (1 ml×3) C, 50 mg A, 20 mg P, (1 ml×2) C |
| 145 | SMA=1:80 | 3 | Abnormal liver function tests | 235/275 | (−)/(−) | ANA=1:640 | 100 A, 10 mg P | |
| 471 | SMA=1:640 | /11,13 | 3 | Abnormal liver function tests | 101/185 | (−)/(−) | SMA=1:80, anti-SLA+ | (1.2×2 ml) C |
OLT, orthotopic liver tranplantation; NA, not available; AST/ALT, aspartate aminotransferase/alanine aminotransferase; HCV, hepatitis C virus; P, prednisone; C, cyclosporin; A, azathioprine; ANA, antinuclear antibodies; SMA, smooth muscle antibodies; SLA, soluble liver antigen; LKM, liver kidney microsome.